Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BeOne Medicines
Regeneron Pharmaceuticals
Genmab
CytomX Therapeutics
Shionogi Inc.
Nanjing Leads Biolabs Co.,Ltd
Nanjing Leads Biolabs Co.,Ltd
Bristol-Myers Squibb
AskGene Pharma, Inc.
Sanofi
Adagene Inc
Incyte Corporation
Hebei Medical University Fourth Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
Hansoh BioMedical R&D Company
Miller Children's & Women's Hospital Long Beach